接受性别肯定激素治疗跨性别女性的前列腺癌发病率与疾病特征:系统综述与Meta分析
该系统综述与Meta分析纳入9项研究(来自6个独立数据源,54 342例接受性别肯定激素治疗的跨性别女性,160例前列腺癌),汇总标准化发病比为0.224(95%CI 0.146-0.344),较年龄校正顺性别男性相对降低77.6%。汇总发病率为22.9/10万人年,对照为98.1/10万人年。在有分级数据的36例中,33.3%为ISUP分级组4-5,但严重程度是否与匹配顺性别人群不同仍不确定。
要点
- 跨性别女性接受GAHT后前列腺癌检出发病率显著低于顺性别男性,汇总SIR为0.224。
- 病例层面数据中33.3%为高分级疾病,提示不能将人群发病率降低等同于个体保护。
- 需建立经过验证的PSA阈值和筛查路径,证据确定性很低。
核心结论
- 接受GAHT的跨性别女性中检出的前列腺癌发病率显著低于顺性别男性,但证据确定性很低。
- 病例层面数据包含不可忽视比例的高分级疾病,严重程度是否与匹配顺性别人群不同仍不确定。
- 临床医生不应将人群层面的发病率降低等同于个体层面的保护。
研究设计与样本
- 系统综述与Meta分析,遵循PRISMA 2020,PROSPERO注册号CRD420261369142。
- 检索5个数据库,从建库至2026年4月。
- 纳入报告≥5例接受GAHT且前列腺完整的跨性别女性或性别多元个体前列腺癌发病率或结局的研究。
- 共纳入9项研究,来自6个独立数据源,含54 342例接受GAHT的跨性别女性和160例前列腺癌病例。
- 采用随机效应Meta分析汇总标准化发病比、发病率和记录前列腺癌的比例。
主要发现
- 汇总SIR对比年龄校正顺性别男性为0.224(95%CI 0.146-0.344;κ=2),相对降低77.6%。
- 汇总发病率为22.9/10万人年,对照为98.1/10万人年。
- 在36例有报告分级的病例中,33.3%为ISUP分级组4-5。
- PSA范围为6.5-18.0 ng/ml,未进行汇总。
关键数值与推荐
- 汇总SIR为0.224(95%CI 0.146-0.344),相对降低77.6%。
- 汇总发病率22.9/10万人年 vs 对照98.1/10万人年。
- 36例有分级数据中33.3%为ISUP分级组4-5。
- PSA范围6.5-18.0 ng/ml,未汇总。
临床怎么用
- 临床医生不应将人群层面前列腺癌发病率降低等同于个体层面保护。
- 对接受GAHT的跨性别女性仍需关注前列腺癌风险,尤其高分级疾病可能。
- 需建立经过验证的PSA阈值和筛查路径。
局限性
- 证据确定性很低。
- 分级和分期数据来自少于40例患者,且无匹配的顺性别对照。
- PSA数据未汇总。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Transgender women (TGW) retain lifelong prostate cancer (PCa) risk despite gender-affirming hormone therapy (GAHT), yet its association with PCa incidence and severity is poorly synthesised. This study aimed to quantify pooled PCa incidence in TGW on GAHT relative to cisgender men and characterise disease severity. METHODS: This is a systematic review with meta-analysis per Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 (International Prospective Register of Systematic Reviews: CRD420261369142). Five databases were searched from inception to April 2026. Eligible studies reported PCa incidence or outcomes in ≥5 TGW or gender-diverse individuals with intact prostates receiving GAHT. Screening, extraction, and risk-of-bias assessment (Risk Of Bias In Non-randomized Studies - of Interventions; JBI) were performed in duplicate. Random-effects meta-analyses pooled standardised incidence ratios (SIR), incidence rates, and proportions with recorded PCa. KEY FINDINGS AND LIMITATIONS: Nine studies drawn from six independent data sources (54 342 TGW on GAHT; 160 PCa cases) were included. Pooled SIR versus age-adjusted cisgender men was 0.224 (95% confidence interval = 0.146-0.344; κ = 2), a 77.6% relative reduction; pooled incidence rate was 22.9 versus 98.1 per 100 000 person-years. Among 36 cases with reported grade, 33.3% were International Society of Urological Pathology grade group 4-5; prostate-specific antigen (PSA) ranged from 6.5-18.0 ng/ml and was not pooled. Grade and stage data were derived from fewer than 40 patients with no matched cisgender comparison. CONCLUSIONS AND CLINICAL IMPLICATIONS: Detected PCa incidence is substantially lower in TGW receiving GAHT, on very low certainty evidence. Case-level data include a non-negligible proportion of high-grade disease, but whether severity differs from matched cisgender populations remains uncertain. Clinicians should not equate population-level reduction with individual-level protection. Validated PSA thresholds and screening pathways are needed.
引用
- Oberoi K, Trevaskis I, Hassan S, et al. Prostate Cancer Incidence and Disease Characteristics in Transgender Women Receiving Gender-affirming Hormone Therapy: A Systematic Review with Meta-analysis. Eur Urol Oncol. 2026. PMID: 42881114. doi:10.1016/j.euo.2026.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。